HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype

The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet-to-be-identified partner.

By FiercePharma · May 4, 2026 · via FiercePharma
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
PipelineFierceBiotech ↗
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliv…
May 4, 2026
Axsome Wins FDA Nod for Auvelity in Alzheimer’s Agitation
PipelineBriefing
Axsome Wins FDA Nod for Auvelity in Alzheimer’s Agitation
Auvelity, already cleared for depression, becomes the first non-antipsychotic treatment for agitation in Alzhe…
May 4, 2026
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
PipelineFiercePharma ↗
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ s…
May 3, 2026